Glenmark to commercialize Ryaltris in Australia and New Zealand
Glenmark Pharmaceuticals Limited has announced that its subsidiary Glenmark Speciality S.A. has entered into a licensing agreement with Seqirus Pty. Ltd. to commercialize Ryaltris in Australia and New Zealand. Seqirus is a part of an Australian-based speciality biotechnology company, CSL Limited.
Ryaltris (olopatadine hydrochloride (665 mcg) and mometasone furoate (25 mcg)) is an investigational fixed-dose combination nasal spray of an antihistamine and a steroid, to be used for treating the symptoms associated with seasonal allergic rhinitis (SAR) in patients over 12 years of age.
As per the agreement, Glenmark will supply the product and Seqirus would look after the regulatory filing and commercialization of the product in Australia and New Zealand. Glenmark would be paid an upfront payment and also the regulatory and commercial milestone payments by Seqirus.
It is found that nearly 20 per cent of Australia’s population suffers from allergic rhinitis annually, which leads to a reduction in quality of life and functional impairments.
In May 2018, Glenmark had filed a New Drug Application (NDA) for Ryaltris with the USFDA. It has plans to commercialize it in several key markets globally and would explore commercial partnerships in the markets in which the company has no presence.
On Thursday, the stock closed at Rs. 581.65 per share on BSE. On Friday, in the morning trading session, it surged by 1.6 per cent and made an intra-day high of Rs. 590.80.